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Abstract 
Purpose: We performed this study to analyze the clinical features and prognosis of Korean 
patients with liposarcoma.  
Patients & Methods: Between October 1986 and April 2013, 231 patients who were diagnosed 
with liposarcoma by histologic examination were enrolled in this study.  
Results: The distribution of histologic subtypes was well-differentiated (n = 97, 42%), myxoid (n = 
74, 32%), dedifferentiated (n = 32, 13.9%), pleomorphic (n = 15, 6.5%), and round-cell liposarcoma 
(n = 13, 5.6%). The majority of liposarcomas were located in the lower extremities (35.5%) and 
retroperitoneum (34.2%). Prognosis was worse for the trunk group compared with the extremity 
group (median disease-free survival [DFS] 3.3 vs. 9.9 years, respectively, P <0.001). Median DFS 
was significantly worse in patients with high grade histology compared to those with low grade 
histology (16.9% vs. 65.7%, P <0.001). The independent prognostic factors associated with survival 
were histology (hazard ratio [HR] 3.01; 95% confidence interval [CI], 1.82–4.97; P <0.001) and 
primary site (HR 1.80; 95% CI, 1.12–2.89; P = 0.015). Three risk groups with different survival 
outcomes were identified: group 1 (n = 98), no risk factors; group 2 (n = 92), one risk factor; and 
group 3 (n = 41), two risk factors.  
Conclusions: Histologic subtype and primary site were independent prognostic factors for 
curatively resected liposarcoma. A prognostic model for patients with liposarcoma clarified 
distinct groups of patients with good prognostic discrimination. 
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Introduction 
Liposarcoma is the one of the most common soft 
tissue sarcomas (STS), consisting of over 50 different 
malignancies of mesenchymal origin [1, 2]. In adults, 
liposarcoma is the most common STS with an 
estimated incidence of 17–25% [3]. It predominantly 
occurs in the 5th to 6th decade of life, with a slight 
predominance in males. The majority of cases arise in 
the extremities, and one third of cases arise in the 
visceral space [1, 3]. Although surgical resection is the 
mainstay treatment for localized disease, many 
liposarcomas progress to advanced disease that is 
either unresectable, metastatic, or both. For advanced 
cases, the mortality rate is high and both local and 
systemic tumor burden can cause significant 
morbidity [4, 5].  
Liposarcoma is divided into 5 subtypes based on 
Evans Classification: well-differentiated, myxoid, 
dedifferentiated, round, and pleomorphic [6]. The 
subtype is characterized by distinct genetic or 
molecular aberrations and clinical outcome [7, 8]. 
Well-differentiated and myxoid liposarcoma are 
low-grade tumors, whereas dedifferentiated, 
round-cell, and pleomorphic liposarcoma are 
high-grade tumors. Low-grade histology depicts a 
low frequency of metastasis and high-grade tumors 
often manifest with clinically aggressive behavior 
resulting in distant metastasis [9-11]. However, 
despite the heterogeneity of liposarcoma, most 
previous studies have depicted only a subset of 
liposarcoma cases.  
 In this study, we analyzed a large population of 
patients who underwent curative resection for 
liposarcoma. We analyzed the clinicopathologic 
features and outcomes in these patients. We further 
explored independent prognostic factors and devised 
a prognostic model to facilitate decision making in 
clinical practice.  
Methods 
Patients 
Between October 1986 and April 2013, 231 
patients, who were diagnosed with liposarcoma by 
histologic examination, at Yonsei University Health 
System, Samsung Medical Center, Ilsan Paik Hospital, 
Seoul Medical Center and Busan Paik Hospital were 
enrolled. The criteria for inclusion were as follows: (1) 
pathologically confirmed diagnosis of liposarcoma; 
(2) a complete set of clinical information, which was 
defined by patient demographics, primary tumor site, 
stage, treatment record, and vital status; and (3) the 
absence of distant metastasis. 
Liposarcomas were classified into 5 histologic 
subgroups based on Evans Classification [6] as 
well-differentiated, myxoid, dedifferentiated, round, 
and pleomorphic. The primary lesion sites were 
categorized into 7 groups including the lower 
extremities, upper extremities, thoracic cavity, trunk, 
retroperitoneum, inguinal area, and the head and 
neck. A primary site was considered as being in the 
upper extremities when it was at or beyond the 
shoulder joint, and as the lower extremities when it 
was located in the thigh or leg. Retroperitoneal 
tumors were defined, according to the surgical record, 
as whether any of the following resections were 
performed (colon, small bowel, pancreas, spleen, 
bladder, and uterus). Tumor burden was determined 
by the maximum diameter of the primary tumor at the 
time of surgery. The resection margin was determined 
by gross and microscopic examinations and a 
negative margin was defined as when there was no 
evidence of tumor cells within ≥1 mm from the edge 
of the specimen. Administration of postoperative 
adjuvant radiotherapy or chemotherapy was 
recorded. This study was carried out in accordance 
with the Declaration of Helsinki and approved by the 
Institutional Review Board. Patient information was 
de-identified and IRB waived informed consent from 
study subjects.  
Statistical analyses 
The primary end-point was to assess survival 
outcome using the Kaplan-Meier method. The 
disease-free survival (DFS) was defined as from the 
time of surgery to initial tumor relapse or death. 
Overall survival (OS) was defined as from the date of 
diagnosis to date of death related to the disease or 
complications. Duration of follow up was defined 
from the time of diagnosis to death. In the case of 
death, it was classified as an “event” and, in the case 
of loss of follow up, it was censoring up to that time. 
Survival rates were compared using the log-rank test. 
OS and DFS were assessed with respect to following 
factors: age, sex, histologic subtype, resection margin 
(negative or positive), primary site, tumor burden, 
and adjuvant treatment. Multivariate analysis was 
performed using stepwise Cox proportional hazards 
regression modeling. Two-sided P-values ≤0.05 were 
considered statistically significant. 
Results 
Patient characteristics 
Two-hundred and thirty-one patients who 
underwent surgical resection were analyzed. The 
clinical characteristics of the enrolled patients are 
presented in Table 1. There were 90 females and 141 
males with median age of 55 years (range, 18–90). 
Median tumor size was 13 cm (range, 1–48), and 
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approximately two-thirds of cases (61.9%) had 
negative resection margins. The majority of 
liposarcomas were located in the lower extremities 
(35.5%) and retroperitoneum (34.2%).  
The distributions of histologic subtypes were as 
follows: well-differentiated (n = 97, 42%), myxoid (n = 
74, 32%), dedifferentiated (n = 32, 13.9%), 
pleomorphic (n = 15, 6.5%), and round-cell (n = 13, 
5.6%), respectively. Patients were dichotomized into 
low (well-differentiated and myxoid types) and 
high-grade groups (dedifferentiated, round, and 
pleomorphic types) according to histologic type. 
There were 171 (74.0%) patients with low-grade and 
60 (26%) patients with high-grade liposarcoma.  
Adjuvant therapy was administered in 82 
patients (35.5%), of which 71 (86.6%) and 15 (18.3%) 
received radiotherapy or chemotherapy, respectively. 
The adjuvant treatment was introduced in 29.2% of 
patients with low-grade and 53.3% of those with 
high-grade liposarcoma, respectively. High-grade 
tumors were significantly associated with older age (P 
= 0.02), retroperitoneal location (P = 0.01), positive 
resection margins (P <0.01), and adjuvant treatment (P 
<0.01). 
Survival analyses 
With a median follow-up time of 3.38 years, the 
5-year DFS and OS rates for all patients were 54.5% 
and 75.1%, respectively. The 5-year DFS according to 
histologic subtypes were 67.8%, 63.5%, 22.1%, 25.2% 
and 20.5% for well-differentiated, myxoid, 
dedifferentiated, pleomorphic, and round-cell 
liposarcoma, respectively (Table 2). The 5-year OS 
according to histologic subtypes were 87.1%, 79.4%, 
49.0%, 50.0%, 42.3% for well-differentiated, myxoid, 
dedifferentiated, pleomorphic, and round-cell 
liposarcoma, respectively. Kaplan-Meier analysis 
revealed that DFS was significantly worse in patients 
with high-grade histology compared to those with 
low-grade histology (16.9% vs. 65.7%, P <0.001, Figure 
1A). The 5-year OS rates for high and low-grade 
tumors were 47.8% and 83.5%, respectively (P <0.001, 
Figure 1B). The most favorable prognoses were 
observed in patients with liposarcoma located in the 
inguinal/genitalia regions (80.8%) and the extremities 
(64.8% for the upper extremities and 77.8% for the 
lower extremities), whereas the prognoses were 
reduced in those with liposarcoma located in the 
trunk (including the retroperitoneum), 
intra-abdomen, and thoracic cavity (41.8%, 46.4%, and 
40.1%, respectively; P = 0.002, Figure 2A). For the 
primary lesion sites, prognoses were worse for the 
trunk group (thoracic cavity, retroperitoneum and 
intra-abdomen) compared with the extremities group 
(inguinal/genitalia, upper/lower extremity and 
head/neck) with a median 5-year DFS of 3.3 and 9.9 
years, respectively (P <0.001, Figure 2C). Similar 
patterns were noted for the OS; 5-year OS was 
significantly worse in the trunk group compared with 
the extremities groups (median OS, 10.9 vs.15.2 years; 
P <0.001; Figures 2B and 2D). 
 
Table 1. Patient characteristics. 
Variables Total (N=231, 
%) 
Low (n=171) High (n=60) P value 
Age (Median) 55 (18-90) 53 (18-88) 60 (22-90) 0.02 
Gender    0.54 
Male 141 (61.0) 102 (59.6) 39 (65.0)  
Female 90 (39.0) 69 (40.4) 21 (35.0)  
Histologic variant     
 Well differentiated 97 (42.0) - -  
Myxoid 74 (32.0) - -  
Dedifferentiated 32 (13.9) - -  
Pleomorphic 15 (6.5) - -  
Round 13 (5.6) - -  
Primary site    0.01 
Lower extremity 82 (35.5) 68 (39.8) 14 (23.3)  
Retroperitoneum 79 (34.2) 54 (31.6) 25 (41.7)  
Thoracic cavity 20 (8.7) 11 (6.4) 9 (15.0)  
Intra-abdominal 15 (6.5) 8 (4.7) 7 (11.7)  
Inguinal and genital 14 (6.0) 12 (7.0) 2 (3.3)  
Upper extremity 11 (4.8) 9 (5.3) 2 (3.3)  
Head and Neck 10 (4.3) 9 (5.2) 1 (1.7)  
Tumor burden     
 Median (cm, range) 13 (1-48) 13 (1-48) 13.5 (2-36) 0.76 
Margin    <0.01 
 Negative 143 (61.9) 117 (68.4) 26 (43.3)  
 Positive 88 (38.1) 54 (31.6) 34 (56.7)  
Adjuvant treatment    <0.01 
No treatment 149 (64.5) 121 (70.8) 28 (46.7)  
Radiotherapy 71 (30.7) 44 (25.7) 27 (45.0)  
Chemotherapy 15 (6.5) 7 (4.1) 8 (13.3)  
 
Table 2. Analysis of Histologic Subtypes in Survival Outcome. 
Histologic Variant Total 5-Year 
DFS(%) 
5-Year OS(%) P 
Well differentiated 97 67.8 87.1  P < 0.001 
Myxoid 74 63.5 79.4   
Dedifferentiated 32  22.1 49.0   
Pleomorphic 15  25.2 50.0   
Round 13  20.5 42.3  
 
 
A prognostic model for patients with 
liposarcoma 
According to univariate analyses, sex, age, 
resection margin, tumor diameter, histologic subtype, 
and primary lesion site were associated with DFS and 
OS. In the multivariate Cox proportional model, 
histologic subtype and primary site were significant 
independent risk factors for DFS and OS (Table 3). 
Among them, high-grade liposarcoma was 
significantly associated with a shorter DFS (hazard 
ratio [HR] 3.01; 95% confidence interval [CI], 
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1.82–4.97; P <0.001, Table 3). In addition, liposarcoma 
located in the trunk was a significantly poor 
prognostic factor for DFS (HR 1.80; 95% CI, 1.12–2.89; 
P = 0.015). However, there were no significant 
associations with tumor relapse and mortality in 
terms of median tumor diameter, sex, age, adjuvant 
treatment, or resection margin status. Similar 
relationships were noted for OS (Table 3). 
 
 
 
 
 
Table 3. Prognostic factors for overall and disease free survival in 
study subjects. 
Variables DFS OS 
 HR (95% CI) P HR (95% CI) P 
Histologic subtype 
(High vs Low) 
3.01 (1.82-4.97) <0.001 3.22 (1.74-5.94) <0.001 
Primary site  
(Trunk vs Extremity) 
1.80 (1.12-2.89) 0.015 2.01 (1.07-3.77) 0.029 
Margin status  
(negative vs positive) 
0.99 (0.60-1.61) 0.958 1.09 (0.59-2.01) 0.795 
Tumor burden  
(≤13 cm vs > 13cm) 
1.04 (0.64-1.68) 0.874 1.25 (0.65-2.38) 0.507 
Age (≤60yr vs >60yr) 1.19 (0.76-1.88) 0.450 1.52 (0.85-2.71) 0.158 
Sex (Male) 1.17 (0.75-1.82) 0.480 1.05 (0.59-1.88) 0.869 
Adjuvant Tx.  1.29 (0.82-2.04) 0.270 1.31 (0.73-2.35) 0.361 
 
 
 
Figure 1. Survival outcome according to histologic subtypes. (A) DFS and (B) OS. 
 
 
Figure 2. Survival outcome according to primary site. DFS (A) and OS (B) for each primary site. DFS (C) and OS (D) for the trunk and extremity sites.  
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Figure 3. DFS (A) and OS (B) by prognostic model. Group 1, no risk factor; group 2, one risk factor, group 3, two risk factors. 
 
Using the independent prognostic factors 
(histologic grade and primary site), prognostic 
grouping was performed according to the following 
criteria: group 1(n = 98), no risk factors; group 2 (n = 
92), one risk factor; and group 3 (n = 41), two risk 
factors. Kaplan-Meier survival curves according to the 
prognostic index are shown in Figure 3. The 
prognostic model separated patients into three risk 
groups with significantly different survival outcomes. 
The 5-year DFS rates for groups 1, 2, and 3 were 
73.6%, 50.8%, and 19.2%, respectively (Figure 3A). The 
5-year OS rates for groups 1, 2, and 3 were 89.2%, 
74.8%, and 41.4%, respectively (Figure 3B). 
Discussion  
In the present study, we investigated the 
clinicopathologic characteristics of primary 
liposarcoma. To our knowledge, this is the most 
up-to-date report providing a comprehensive 
epidemiological and prognostic evaluation in a large 
Asian liposarcoma population. In addition, we 
established a prognostic model to facilitate 
risk-adapted therapeutic strategies.  
Liposarcoma accounts for ~20% of STS cases in 
adults [12]. Accumulating evidence has suggested 
that major histologic subtypes of liposarcoma have 
differing clinical outcomes. Regarding incidence, 
previous studies have described few specific subtypes 
or organ sites and most of patients enrolled in these 
studies were Caucasian [13-17]. Therefore, though 
histologic classification is considered the most 
relevant prognostic factor for survival, there is limited 
prevalence data in Asian patients. We previously 
reported the clinical characteristics and outcome of 
curatively resected liposarcoma [18]. However, this 
was a single-center investigation with 94 cases, 
therefore, in the present study, we investigated a large 
homogenous Korean population and conducted 
subgroup analysis. A previous study indicated that 
the liposarcoma subtype distribution in Western 
patients was well-differentiated (46%), 
dedifferentiated (18%), myxoid (18%), round-cell 
(10%), and pleomorphic (8%) [19]. The present study 
in Korean patients demonstrated a similar frequency 
of histologic subtype, in which the most common 
types were well-differentiated followed by myxoid 
and dedifferentiated types. 
 In the present study, the DFS and OS were well 
stratified according to histologic subtype. 
Well-differentiated and myxoid type were defined as 
low-grade whereas dedifferentiated, round, and 
pleomorphic liposarcoma were considered 
high-grade. The 5-year DFS and OS were significantly 
different between the two groups. Multivariate 
analyses demonstrated that histology was an 
independent prognostic factor for survival. These 
findings are congruent with those of Dalal et al. [19] 
who evaluated 801 nomograms for liposarcoma 
patients and who noted similar survival outcomes to 
those presented here. Confirming that histologic 
subtype is a strong, independent, prognostic factor for 
survival in patients with liposarcoma. 
Regarding the primary sites, nearly two-thirds of 
tumors were located in the lower extremities and 
retroperitoneum. This finding is consistent with 
previous Western studies demonstrating that 
25–33.4% of primary lesions were retroperitoneal [19, 
20]. In addition, the present study demonstrated that 
extremity sites had a significantly favorable DFS 
compared with retroperitoneal sites. Previous studies 
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have considered the lower extremities to represent the 
groin, thigh, or leg, whereas retroperitoneal tumors 
were those found in the as bowel, kidney, pancreas, 
bladder, and uterus. However, in the present study, 
we defined the inguinal/genitalia as the groin, thigh, 
bladder, and uterus. Contrary to patients with 
retroperitoneal tumors, those with tumors in the 
inguinal/genitalia area demonstrated a favorable 
survival outcome. Furthermore, we also 
demonstrated that those with lesions in the head and 
neck had better survival compared to those with 
lesions in the trunk. The newly classified favorable 
subgroups (inguinal/genitalia) might have been 
misclassified as the poor survival group (trunk) in 
previous studies. Therefore, we have elucidated the 
prognostic role of primary tumor sites in liposarcoma 
with increased clarity.  
 To enhance risk-based prediction after curative 
resection, we established a prognostic model. Primary 
lesion site and histologic subtype were significant 
independent prognostic factors, thereby, we 
performed prognostic grouping based on a scoring 
system for these factors. This yielded three distinctive 
groupings with differing survival outcomes according 
to the number of risk factors present. Given the poor 
prognosis of patients with >1 risk factors, this 
subgroup of patients may benefit from more 
aggressive pre and postoperative treatments; 
therefore, aggressive postoperative treatment in the 
context of clinical trials may be needed for group 2. 
The role of adjuvant chemotherapy or 
radiotherapy is poorly defined in patients with 
liposarcoma. In a retrospective study that included 
112 patients with liposarcoma who underwent 
perioperative radiotherapy, Zagars et al. [[21]] 
showed that outcome was mainly determined by 
histologic subtype. Patients with well-differentiated 
and myxoid liposarcoma achieved a local control rate 
of 90%, whereas those with pleomorphic liposarcoma 
high a high incidence of local (37%) or distant (41%) 
recurrence. In the present study, the impact of 
adjuvant treatment was not statistically significant. 
For metastatic or unresectable STSs, despite first-line 
standard treatment using a doxorubicin-containing 
regimen, the median OS was dismal (12 months) [22]. 
In addition, gemcitabine and docetaxel are frequently 
used as a second-line treatment for STSs [23], 
although the response rate was been reported as 16%, 
with two patients exhibiting stable disease. A 
potential breakthrough in the management of STSs 
has been the recent introduction of pazopanib [24]. 
However, pazopanib has shown favorable efficacy in 
leiomyosarcoma and synovial sarcoma, but not in 
liposarcoma [25]. The underlying biological 
mechanisms of poor response to chemotherapy or 
radiotherapy have not been defined, but they might 
partially depend on the heterogeneity of histologic 
subtypes. Therefore, further histology-based 
strategies are strongly warranted.  
This is the first study to comprehensively review 
and describe the clinical features and prognosis of 
Asian liposarcoma patients. Histologic subtype and 
primary tumor site were independently associated 
with disease-specific survival. The proposed model 
for primary liposarcoma demonstrated distinct 
groups of patients with good prognostic 
discrimination. We believe that the findings of the 
present study could facilitate further prospective 
studies and confirm an alternative clinical 
decision-making process for Asian patients with 
liposarcoma. 
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